Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

http://www.wikidata.org/entity/Q34136595

about

Topical pimecrolimus for eczema Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis.Calcineurin inhibitors and rapamycin: cancer protection or promotion?A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.Pimecrolimus cream 1% in the management of atopic dermatitis in pediatric patients: a meta-analysis Gender differences in depression and anxiety among atopic dermatitis patients.A proposal: Atopic Dermatitis Organizer (ADO) guideline for children Therapeutic potential of macrolide immunosuppressants in dermatology.Pimecrolimus for the treatment of inflammatory skin disease.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.The role of topical calcineurin inhibitors in atopic dermatitis.Pimecrolimus -- an anti-inflammatory drug targeting the skin.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.Stress in mothers of young children with eczema.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum.Atopic dermatitis prevention.A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.A systematic review of the safety of topical therapies for atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Pimecrolimus versus topical corticosteroids in dermatology.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Molecular pathogenesis and clinical implications of eczema herpeticum.Pathways to managing atopic dermatitis: consensus from the experts Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use.Warm, humid, and high sun exposure climates are associated with poorly controlled eczema: PEER (Pediatric Eczema Elective Registry) cohort, 2004-2012.Does eczema lead to asthma?Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.What's new in atopic eczema?Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis Pimecrolimus cream in the management of patients with atopic eczema.Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.

P2860

Q24243250-D65C003F-F75E-4FEC-AC37-C22BBF585068 Q31149849-5646F62E-2A68-45B7-BB23-1161BE44B16B Q34497913-30C9AD9F-2BA5-452C-8565-4A1DEA248607 Q34552586-DCCFF72C-1953-4675-9B0A-94557E4E2363 Q34578721-FF8400F4-08CE-4C7D-80F4-3E6C6BC444C9 Q34632467-AA091033-19DD-45C2-8A32-B52B2C376AED Q35077866-CC03AE32-52C8-4C49-962D-B5D8FA9EC82E Q35137660-C1500060-EC96-4339-B639-09D934C15A6D Q35215234-B73A1154-8A01-4E38-BDA1-BC4AAD6A19DD Q35502659-AF24B7DC-1EAA-4832-A0DC-51CEC90D1620 Q35680649-DD1A01F4-3062-4E32-9C95-2C02C08C5190 Q35688189-31C5B55B-1AC7-4C86-9A7D-5E4A97C5287E Q35809490-C7F76246-FBCB-4117-AEB1-848858ABD900 Q35952647-340467AA-10C6-4BC2-B723-0FF8DF2003C9 Q35961095-E424B7E5-0165-4B5A-BF9E-2AF52115BA5D Q36042131-3B922F9F-CE44-45C7-AF1A-DDD34C5569EB Q36155772-EAD3AA86-0646-4542-9A9D-1050377DD0F1 Q36214247-40441622-00C1-4AF1-B838-AB4EB12BA83B Q36222741-7AD6C33F-34D8-491F-9AC5-9CBC127414A2 Q36305883-8D16F44F-ED3F-4DED-ADC7-2D8348905D8D Q36466794-A5B72949-708B-44C6-BD80-E68DE43A9C83 Q36480608-7B00C058-F0B5-40C7-B75E-867297E27A32 Q36574341-F622A32E-234F-4617-AAC6-8142FEAC9D89 Q36681795-65B6DF03-605D-4FB2-AD81-7160E5E36F67 Q36708358-0B23180B-E59C-438B-BFEC-EAB5646CF06C Q36861654-0A38484A-6941-4A1B-B148-41231A1FDA24 Q36892767-5CDE4F2E-B44A-44C1-B753-EE713DCC2381 Q36895865-343DCC7E-226E-4DD7-B3E1-AA431787B625 Q37049981-B582FB02-7732-40E9-9F4A-34AEE8A84C05 Q37049990-B466F600-2865-42B0-B1FA-7B02A7F81529 Q37213870-01F231DD-4320-4067-82C2-E4CB9CBD7A93 Q37258723-ECA2DC6A-8C82-4E8D-BA75-072D15FF52C9 Q37327264-F5BC0555-A073-4E1E-B1B3-581596E517E2 Q37407574-77680B93-EC45-4C39-8952-7A140C72F382 Q37526675-CFFBBC92-1C93-4E40-B916-6642FE230459 Q37731539-05136956-03A6-4F66-BBA4-E5130979952E Q37740142-54D17C87-96BA-40FC-86C5-F396EE736724 Q37822710-4B6A4223-3947-40B9-8FBF-D9E78E98CFE8 Q37857666-2D4EF44A-591B-4F8A-A394-A3E5C3E1FBD4 Q37865056-E4B809BE-93DD-4E56-AEB5-224DCB1B053B

P2860

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.

http://www.wikidata.org/entity/Q34136595

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@ast

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@en

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@nl

type

label

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@ast

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@en

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@nl

prefLabel

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@ast

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@en

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@nl

P1433

Q34136595-C2198603-94DE-4845-BC0F-A61CF437CC1E

P1476

Q34136595-74063983-DD24-4081-8DEF-761AA925324C

P2093

Q34136595-1A87B1FC-152C-4593-8A13-5B360872F922

Q34136595-38160AE9-B814-4DAE-B5C6-30B5F243648E

Q34136595-48918672-DD26-456E-90FA-D8F815894B95

Q34136595-5466E9F4-8102-400F-A8A0-DC78814306DA

Q34136595-6B6D1E09-3C71-4758-A5C5-E2EE9EE00E5B

Q34136595-75B65B36-4FB8-48FB-A371-3ECF089379B0

Q34136595-8E982687-80AC-4673-B753-0E102B58DD59

Q34136595-95F2CA52-1A22-4753-9E9E-35EDA42A4C3F

Q34136595-AE5CA258-B62E-4B74-B5E0-FE14B50BF67C

Q34136595-DA9B29CE-01C1-48B8-BE49-B09EE93DE7E2

P304

Q34136595-78B89755-3552-41BB-8A1A-338652CA478F

P31

Q34136595-0DD915B0-D04F-499E-9F58-9CEB07343C22

P356

Q34136595-CCC9D29D-82C4-48DE-8FDB-5A7FF6A9E3AD

P407

Q34136595-6720573D-4421-41D6-A146-861C58DFAD2B

P433

Q34136595-883EABFD-1898-4DC5-A92C-197141D3C669

P478

Q34136595-0C3EAD25-44D8-4D58-8BE7-A8475A28432E

P577

Q34136595-CEFE93C7-92DD-4CC7-B3E6-9F80C97827F1

P5875

Q34136595-ACE65D00-429A-4D08-AEF7-4171DA2726F0

P698

Q34136595-965D80D7-5431-4DE7-B75A-A2C344C1585A

P356

P1433

P1476

Efficacy and safety of pimecro ...... atopic dermatitis in children.

@en

P2093

Ahmed Manjra

http://www.w3.org/2001/XMLSchema#string

Attila Dobozy

http://www.w3.org/2001/XMLSchema#string

Carle Paul

http://www.w3.org/2001/XMLSchema#string

Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group

http://www.w3.org/2001/XMLSchema#string

Jan D Bos

http://www.w3.org/2001/XMLSchema#string

Kim Papp

http://www.w3.org/2001/XMLSchema#string

Mark Goodfield

http://www.w3.org/2001/XMLSchema#string

Michael Graeber

http://www.w3.org/2001/XMLSchema#string

Robert Cherill

http://www.w3.org/2001/XMLSchema#string

Ruggero Caputo

http://www.w3.org/2001/XMLSchema#string

P304

e2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.110.1.E2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11281790

http://www.w3.org/2001/XMLSchema#string

P698

12093983

http://www.w3.org/2001/XMLSchema#string